Sign in
Not yet recruitingNo phase

Gene activity in egg-surrounding cells of women with diminished ovarian reserve having IVF

Compares molecular markers in women with low egg supply and normal supply undergoing IVF.

Key facts

Who runs it
Assiut University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Hippo-Related Competing Endogenous RNA (ceRNA) Network Dysregulation and In Vitro Fertilization (IVF) Outcomes in Women With Diminished Ovarian Reserve
Status
Not yet recruiting
People taking part
70 people, planned
Started
1 Aug 2026
Expected to end
1 Oct 2028
Type of study
Observational, 2 groups
Record updated
22 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women going through IVF or ICSI because of infertility. One group has a low egg reserve (diminished ovarian reserve). The other group has a normal egg reserve, with infertility from other causes such as male or tube problems.

Age
18 Years to 40 Years
Sex
Women only
Disease stage
Infertility for at least one year, primary or secondary. The low egg reserve group needs at least two of: AMH ≤1.1 ng/mL, antral follicle count ≤7, basal FSH ≥10 IU/L.
Earlier treatment
People who had hormone therapy in the last three months cannot join.
Biomarker or test result
For the low egg reserve group: at least two of AMH ≤1.1 ng/mL, antral follicle count (AFC) ≤7, basal FSH ≥10 IU/L.

Main reasons for not taking part

  • Polycystic ovary syndrome (PCOS) or endometriosis
  • Ovarian tumors or cancer
  • Severe body-wide diseases affecting fertility, or metabolic syndrome
  • Connective tissue disorders
  • Hormone therapy within the last three months

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Women undergoing In Vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI) cycles
  • Infertility duration of at least one year
  • Primary or secondary infertility

Who cannot take part

  • Hormonal therapy within the last three months
  • Polycystic Ovary Syndrome (PCOS)
  • Ovarian tumors or malignancy
  • Severe systemic diseases affecting fertility
  • Metabolic syndrome
  • Connective tissue disorders
  • Endometriosis
  • Refusal to participate

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 40 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Diminished Ovarian Reserve (DOR) is an important cause of female infertility and is associated with poor ovarian response and lower pregnancy rates during In Vitro Fertilization (IVF). The molecular mechanisms underlying impaired follicular development in DOR remain incompletely understood. Increasing evidence suggests that non-coding RNAs and components of the Hippo signaling pathway play important roles in granulosa cell proliferation, apoptosis, and follicular development.

Read full original descriptionShow less

This prospective observational cohort study aims to investigate the expression of the long non-coding RNA (lncRNA) Nuclear Paraspeckle Assembly Transcript 1 (NEAT1), microRNA (miRNA)-181a-5p, Hippo pathway components including Yes-Associated Protein 1 (YAP1) and Connective Tissue Growth Factor (CTGF), and Insulin-Like Growth Factor 1 (IGF1) in follicular fluid-derived cells from women with DOR undergoing IVF compared with women with normal ovarian reserve. The study will also evaluate relationships among these molecular markers and IVF outcomes, including oocyte quality, number of retrieved oocytes, and embryo developmental potential.

The 2 groups in the trial

  • Group 1: Control Group

    Group 1: Control Group Women with normal ovarian reserve undergoing In Vitro Fertilization (IVF) due to non-ovarian causes of infertility such as male factor infertility or tubal factor infertility.

  • Group 2: DOR Group

    Group 2: DOR Group Women diagnosed with diminished ovarian reserve according to at least two of the following criteria: Anti-Müllerian Hormone (AMH) ≤1.1 ng/mL Antral Follicle Count (AFC) ≤7 Basal Follicle-Stimulating Hormone (FSH) ≥10 IU/L

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Investigating the Dysregulation of the Hippo-Related ceRNA Network and Its Impact on IVF Outcomes in Patients With Diminished Ovarian Reserve (DOR)
Plain-language title
Gene activity in egg-surrounding cells of women with diminished ovarian reserve having IVFGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Fit questions
Built from NCT07658846, who can take part
Record updated
22 June 2026